Patent application number | Description | Published |
20080226598 | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems - Methods are provided for generating immune responses utilizing alphavirus-based vector systems. | 09-18-2008 |
20090081254 | HIV VACCINE FOR MUCOSAL DELIVERY - This invention is directed to pharmaceutical compositions comprising an HIV antigen and a mucosal adjuvant and methods for raising an immune response in a subject by administering these compositions. Preferably, the pharmaceutical compositions of the invention can be used to treat or prevent HIV infection. | 03-26-2009 |
20090304740 | MODIFIED HIV ENV POLYPEPTIDES - Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 12-10-2009 |
20100092502 | MODIFIED HIV ENV POLYPEPTIDES - Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided. | 04-15-2010 |
20100266631 | Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems - Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses. | 10-21-2010 |
20100285062 | COMBINED MUCOSAL AND PARENTERAL IMMUNIZATION AGAINST HIV - HIV antigens are mucosally administered in one or more priming immunization(s), and then HIV antigens are parenterally administered in one or more boosting immunization(s). Thus the invention provides a method for raising an immune response in a patient, comprising: (i) administering a HIV antigen to the patient via a mucosal route; and then (ii) administering a HIV antigen to the patient via a parenteral route. The antigens will typically be adjuvanted. Preferred mucosal immunizations are via the intranasal route using a detoxified mutant of | 11-11-2010 |
20100316698 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described. | 12-16-2010 |
20110020396 | HIV Envelope-CD4 Complexes and Hybrids - Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided. | 01-27-2011 |
20110212164 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described. | 09-01-2011 |
20120269851 | EXPRESSION CASSETTES ENDCODING HIV-1 SOUTH AFRICAN SUBTYPE C MODIFIED PROTEINS - The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof. | 10-25-2012 |
20120276128 | HIV Envelope-CD4 Complexes and Hybrids - Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided. | 11-01-2012 |
20140220060 | HIV-1 SOUTH AFRICAN SUBTYPE C ENV PROTEINS - The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof. | 08-07-2014 |
20140242152 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF - This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions. | 08-28-2014 |